The urgency to treat optimally and to target: Avoiding long-term complications in type 2 diabetes with a focus on GLP-1 receptor agonists

Auteurs-es

  • Lionel Noronha, MD

Résumé

The wave of diabetes continues to increase in Canada and around the world. According to national data, 3.4 million Canadians were living with diabetes (type 1 and type 2 combined) in 2017–2018, compared to 1.3 million in 2000–2001. It is well-accepted that diabetes is a major cause of death and is the leading cause of renal failure, lower limb amputations and blindness in adults.

Biographie de l'auteur-e

Lionel Noronha, MD

Dr. Lionel Noronha graduated from the University of Toronto medical school in 1990 and completed his family medicine residency there in 1992. He was awarded the Gaynor Dawn Memorial scholarship in family medicine. He is the medical director of the Stirling Manor and the lead physician for the Belleville family health organization. He has been a clinical investigator in numerous studies and also has published in peer-reviewed journals. He has a passion for CME and has given over 250 talks to other physicians as well as nurses, pharmacists and diabetic educators.

Références

Public Health Agency of Canada. Canadian Chronic Disease Surveillance System (CCDSS) [Internet]. Public Health Agency of Canada. 2017 [accessed 2019 Sept 2013].

Gaede P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008 Feb 7;358(6):580-591.

DCCT Research Group. Diabetes control and complications trial (DCCT): update. Diabetes Care.1990:427-433.

King P, Peacock I, Donnelly R. The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmcol. 1999:48(5):643.

Duckworth W, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009:360;2:129-139.

ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008:358(24):2560-2572.

Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005:353(25): 2643-2653.

Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007:356(24):2457-2471.

Green JB, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015:373(3):232-242.

Scirica BM, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013:369(14):1317-1326.

Rosenstock J, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019:321(1):69-79.

Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015:373(22):2117-2128.

Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016:375(4):311-322.

Neal B, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017:377(7):644-657.

Wiviott SD, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019:380(4):347-357.

Lipscombe L, et al. Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update. Can J Diabetes. 2020:44(7):575-591.

Marso SP. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016:375:1834-1844.

Husain, M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019:381(9): 841-851.

Aroda VR. Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;4 (9):1724-1732.

Laiteerapong N. The legacy effect in type 2 diabetes: impact of early glycemic control on future (The Diabetes and Aging Study). Diabetes Care. 2019;42(3):416-426.

Lachlin JM. The beneficial effects of earlier versus later implementation of intensive therapy in type 1 diabetes. Diabetes Care. 2021:44(10):2225‑2230.

Téléchargements

Publié

2023-07-12

Comment citer

1.
The urgency to treat optimally and to target: Avoiding long-term complications in type 2 diabetes with a focus on GLP-1 receptor agonists. Can Prim Care Today [Internet]. 12 juill. 2023 [cité 7 avr. 2026];1(S07):2–6. Disponible à: https://canadianprimarycaretoday.com/article/view/1-s07-noronha

Numéro

Special Supplement, July 2023

Rubrique

Articles

Licence

© Canadian Primary Care Today 2023

Licence Creative Commons

Cette œuvre est sous licence Creative Commons Attribution - Pas d'Utilisation Commerciale - Pas de Modification 4.0 International.

Comment citer

1.
The urgency to treat optimally and to target: Avoiding long-term complications in type 2 diabetes with a focus on GLP-1 receptor agonists. Can Prim Care Today [Internet]. 12 juill. 2023 [cité 7 avr. 2026];1(S07):2–6. Disponible à: https://canadianprimarycaretoday.com/article/view/1-s07-noronha